Key facts: Deramiocel Hits HOPE-3 Endpoint; Heart Data NS, FDA Odds 62%

Capricor Therapeutics (CAPR) reported that deramiocel met the primary endpoint in its Phase 3 HOPE-3 trial, improving upper-limb function. However, overall heart function results were not statistically significant. BiopharmaWatch estimated a 62% chance of FDA approval for Deramiocel, with a decision expected soon.

Original reporting
Published Nov 18, 2026, 8:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 8:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Key facts: Deramiocel Hits HOPE-3 Endpoint; Heart Data NS, FDA Odds 62% — source image
Decision brief

The 30-second read

$CAPRBullishMed
01

Why it matters

The primary‑endpoint success is a key catalyst for valuation, moving the probability of FDA approval from speculative to quantifiable.

02

Market read

First‑time disclosure of pivotal trial data provides a fresh trading signal for CAPR and may influence peer biotech valuations.

03

What to watch

Regulatory timing and potential competition from other therapies are not addressed in the article.

Relevance 8/10Novelty 8/10Timing: today's market reaction

Background

Capricor Therapeutics (NASDAQ:CAPR) is a small‑cap biotech focused on gene‑editing therapies for rare cardiac and muscular diseases.

Company-level read

Ticker impact

$CAPRBullishHigh confidence
Context

Capricor Therapeutics reported that its drug deramiocel met the primary endpoint in the Phase 3 HOPE-3 trial, a first‑time disclosure of pivotal data.

Expected impact

likely upward pressure as the market prices in the 62% FDA approval probability.

Evidence & confidence

Trial success is material for a biotech; the article is the first report of the data, making the information novel and actionable.

Market effects

Other gene‑therapy and rare‑disease biotech stocks may see increased interest as the trial success raises sector optimism.

US biotech sector could benefit from the news, with modest spill‑over to Nasdaq biotech indices.

International investors tracking FDA pipelines may adjust exposure to similar companies.

Counterpoint

The 38% chance that the trial fails to meet secondary endpoints or safety concerns could limit upside.

Key entities

  • Capricor Therapeutics

    Biotech developer of deramiocel.

Related articles

$NVDAMed

NVDA Earnings Spark Tech Rally As US Futures Climb — BABA, INTC, ASTS In Focus

Nvidia (NVDA) reported strong Q3 earnings, beating revenue and EPS estimates, driving early premarket gains. Alibaba (BABA) faces scrutiny over ties to a suspected Chinese spy. Intel (INTC) reportedly laid off employees as part of restructuring. Capricor Therapeutics (CAPR) awaits FDA decision on its DMD therapy. AST SpaceMobile (ASTS) faces investor concerns over rocket development. Klarna (KLAR) reported better-than-expected Q3 revenue but missed adjusted EPS estimates.

$NVDAMed

Futures Climb As Nvidia Earnings Boost AI Trade — BABA, INTC, ASTS, CAPR In Focus

Nvidia reported 103% revenue growth to $115.8B, beating estimates. U.S. stock futures rose early Wednesday. Alibaba faces scrutiny over ties to a suspected Chinese spy. Intel confirmed layoffs. Capricor awaits FDA decision on Deramiocel. AST SpaceMobile faces investor concerns over rocket development. Klarna reported Q3 revenue of $1.009B, narrowing losses. Target, Palo Alto Networks, Lowe's, and TJX are set to report earnings.

$SLSMed

‘Pharma Bro’ Shkreli Calls SLS Results ‘Sketch,’ Compares Leukemia Vaccine Data To Capricor’s Deramiocel

SELLAS Life Sciences (SLS) reported that its REGAL trial of the galinpepimut-S cancer vaccine met the primary overall survival endpoint, with median survival of 24 months vs. 14.7 months for the best available treatment. Shares jumped over 200% on the news. Former pharmaceutical executive Martin Shkreli criticized the data, comparing it to Capricor Therapeutics' (CAPR) Deramiocel data and predicting FDA rejection.